Display options
Cite
Amara W, Antoniou S. Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J Suppl. 2016;18:D1-D6doi: 10.1093/eurheartj/suv062.
Amara, W., & Antoniou, S. (2016). Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European heart journal supplements : journal of the European Society of Cardiology, 18D1-D6. https://doi.org/10.1093/eurheartj/suv062
Amara, Walid, and Antoniou, Sotiris. "Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation." European heart journal supplements : journal of the European Society of Cardiology vol. 18 (2016): D1-D6. doi: https://doi.org/10.1093/eurheartj/suv062
Amara W, Antoniou S. Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J Suppl. 2016 Apr 20;18:D1-D6. doi: 10.1093/eurheartj/suv062. Epub 2016 Apr 21. PMID: 28533706.
Copy Download .nbib Format: NLM
Share it on

Eur Heart J Suppl. 2016 Apr 20;18:D1-D6. doi: 10.1093/eurheartj/suv062. Epub 2016 Apr 21.

Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

European heart journal supplements : journal of the European Society of Cardiology

Walid Amara, Sotiris Antoniou

Affiliations

  1. Unité de Rythmologie, GHI Le Raincy-Montfermeil, 10, Rue du Général-Leclerc, Montfermeil 93370, France.
  2. Cardiovascular Medicine, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK.

PMID: 28533706 DOI: 10.1093/eurheartj/suv062

Abstract

Atrial fibrillation (AF) is the most prevalent clinically relevant arrhythmia, affecting millions of individuals in Europe and the USA. Atrial fibrillation increases the risk of stroke; the long-term standard of care for prevention of AF-related stroke is anticoagulation. The use of anticoagulants should be based on the absolute risks of stroke and bleeding and the relative benefit-risk profile of the individual patient. Treatment options include vitamin K antagonists (VKAs) such as warfarin, whose use is long-established but associated with drawbacks, including regular coagulation monitoring requirements and many food and drug interactions. The non-VKA oral anticoagulants are gaining widespread use as alternatives to VKAs, and are supported in treatment guidelines for patients with AF at moderate to high risk of stroke. Adherence to medication is important for the long-term efficacy of any therapy; however, relatively low levels of medication adherence are to be expected in 'real-world' AF patients compared with clinical trials. Experience across several therapy areas, including cardiovascular disease, shows that poor adherence to chronic medication is common. However, simple dosing schedules may be advantageous in this respect, and because long-term outcomes in AF are likely to be influenced by adherence, once-daily dosing has the potential to improve rates of stroke prevention in patients with AF.

Keywords: Adherence; Atrial fibrillation; OAC; Once daily; Rivaroxaban; Stroke prevention

References

  1. Expert Rev Cardiovasc Ther. 2013 Jan;11(1):77-90 - PubMed
  2. Eur Heart J. 2016 Apr 7;37(14 ):1145-53 - PubMed
  3. BMC Cardiovasc Disord. 2013 Dec 01;13:108 - PubMed
  4. Can J Cardiol. 2011 Jan-Feb;27(1):74-90 - PubMed
  5. Eur J Intern Med. 2009 Jan;20(1):63-9 - PubMed
  6. Curr Med Res Opin. 2012 Feb;28(2):195-201 - PubMed
  7. Chest. 2012 Feb;141(2 Suppl):e531S-75S - PubMed
  8. Adv Ther. 2012 Aug;29(8):675-90 - PubMed
  9. Stroke. 1996 Oct;27(10):1760-4 - PubMed
  10. Am J Manag Care. 2012 Mar;18(3):139-46 - PubMed
  11. Age Ageing. 2009 Mar;38(2):140-2 - PubMed
  12. Clin Ther. 2001 Aug;23(8):1296-310 - PubMed
  13. Circulation. 2011 May 31;123(21):2363-72 - PubMed
  14. Thrombosis. 2012;2012:835356 - PubMed
  15. Stroke. 2009 Jan;40(1):235-40 - PubMed
  16. Curr Med Res Opin. 2014 Jul;30(7):1317-25 - PubMed
  17. Am J Health Syst Pharm. 2009 Aug 15;66(16):1471-7 - PubMed
  18. Chest. 2010 Nov;138(5):1093-100 - PubMed
  19. Eur Heart J. 2013 Sep;34(35):2746-51 - PubMed
  20. Gastroenterology. 2013 Jul;145(1):105-112.e15 - PubMed
  21. Am J Manag Care. 2013 Sep;19(9):e325-32 - PubMed
  22. Lancet. 2007 Aug 18;370(9587):604-18 - PubMed
  23. Can J Cardiol. 2012 Mar-Apr;28(2):125-36 - PubMed
  24. Ann Intern Med. 2006 Dec 19;145(12):887-94 - PubMed
  25. N Engl J Med. 2011 Mar 3;364(9):806-17 - PubMed
  26. N Engl J Med. 2009 Sep 17;361(12):1139-51 - PubMed
  27. Stroke. 2009 Apr;40(4):1410-6 - PubMed
  28. Circulation. 2011 Mar 15;123(10):e269-367 - PubMed
  29. Eur Heart J. 2010 Oct;31(19):2369-429 - PubMed
  30. Curr Med Res Opin. 2012 May;28(5):669-80 - PubMed
  31. Stroke. 2005 Jun;36(6):1115-9 - PubMed
  32. Stroke. 1991 Aug;22(8):983-8 - PubMed
  33. Europace. 2015 Apr;17(4):530-8 - PubMed
  34. Circulation. 2015 Jan 27;131(4):e29-322 - PubMed
  35. N Engl J Med. 2011 Sep 15;365(11):981-92 - PubMed
  36. Curr Med Res Opin. 2014 Dec;30(12):2461-9 - PubMed
  37. Europace. 2015 Oct;17(10):1467-507 - PubMed
  38. Patient. 2013;6(3):213-24 - PubMed
  39. N Engl J Med. 2011 Sep 8;365(10):883-91 - PubMed
  40. Thromb J. 2013 Jun 28;11(1):8 - PubMed
  41. Arch Intern Med. 2011 Feb 28;171(4):300-5 - PubMed
  42. Stroke. 2012 Dec;43(12):3442-53 - PubMed
  43. BMJ. 2003 Jan 18;326(7381):153-6 - PubMed
  44. JAMA. 2001 May 9;285(18):2370-5 - PubMed

Publication Types